Procedure: BAV;Procedure: BAV + TAVR;Procedure: SAVR
NULL
Other: Physiotherapy
Device: Active Stimulation;Device: Sham Stimulation
Device: DAV132
Other: Renal clearance examination
Drug: Semaglutide 3 mg;Drug: Semaglutide 7 mg;Drug: Semaglutide B 3 mg;Drug: Semaglutide B 7 mg;Drug: Semaglutide C 3 mg;Drug: Semaglutide C 7 mg;Drug: Semaglutide D 3 mg;Drug: Semaglutide D 7 mg
NULL
Drug: Upadacitinib;Drug: Placebo for Upadacitinib
Drug: Sarilumab SAR153191 (REGN88);Drug: Sarilumab-matching placebo;Drug: Prednisone;Drug: Prednisone-matching placebo;Drug: Prednisone
Drug: BI 1323495;Drug: BI 1323495;Drug: BI 1323495;Drug: Placebo;Drug: Placebo;Drug: Placebo
Drug: Ripasudil eye drops;Drug: Optive eye drops;Procedure: Descemetorhexis
Drug: A4250 (odevixibat);Drug: Placebo
Device: Omnidirectional Deep Brain Stimulation of STN;Device: Directional Deep Brain Stimulation of STN
Diagnostic Test: Duplex Ultrasound (DUS);Diagnostic Test: IVUS with Intraarterial pressure measurement (IAP) if needed
Other: Warm water;Other: Mustard;Other: Ginger
Drug: Tropifexor (LJN452);Drug: Cenicriviroc (CVC)
NULL
Device: Frazier 3 Verio;Device: Frazier 3 UltraPlus
Drug: Methyl Aminolaevulinate 16% Cream
Drug: Nalbuphine ER Tablets;Other: Matching Placebo Tablets
Diagnostic Test: ex-vivo drug response assay
Other: mucous fistula refeeding
Procedure: MICS CABG;Procedure: Conventional CABG
NULL
Drug: ALLN-177
Drug: RELVAR/BREO;Drug: Salbutamol;Device: Smart phone app;Device: HCP Dashboard;Device: Sensors
Diagnostic Test: Transesophageal Echocardiography
Drug: Riciguat Group;Drug: Macitentan Group
Drug: Pembrolizumab;Drug: Epacadostat;Drug: Cetuximab;Drug: Cisplatin;Drug: Carboplatin;Drug: 5-Fluorouracil
Drug: efpeglenatide (SAR439977);Drug: placebo
Drug: Blinatumomab;Drug: Pembrolizumab
Drug: Aclidinium bromide;Drug: Aclidinium bromide/formoterol;Drug: Other COPD medication
Drug: M7583
Drug: Abediterol;Drug: Placebo;Drug: Abediterol;Drug: Placebo;Drug: Abediterol;Drug: Placebo;Drug: Abediterol;Drug: Placebo
Drug: QAW039;Drug: Placebo
Drug: Palbociclib;Drug: Fulvestrant;Drug: Anastrozole;Drug: Letrozole;Drug: Exemestane
Behavioral: Photoaging Mirroring Intervention;Behavioral: Photoaging Mirroring Intervention;Behavioral: Photoaging Mirroring Intervention;Behavioral: Photoaging Mirroring Intervention
Other: Buteyko Breathing Technique
Other: Induced sputum procedure
Drug: MK-4621
Drug: Doxorubicin+cisplatin+ifosfamide;Drug: Doxorubicin+cisplatin+ifosfamide+methotrexate
Drug: Carfilzomib
Drug: MOD-4023;Drug: Somatropin
Drug: Baloxavir Marboxil;Drug: Placebo to Baloxavir Marboxil;Drug: Oseltamivir;Drug: Placebo to Oseltamivir
Device: Anterior cervical discectomy with prosthetic disc replacement / ESP.;Device: Anterior cervical discectomy with prosthetic disc replacement / Squale.;Device: Anterior cervical discectomy with prosthetic disc replacement / ESP.;Device: Anterior cervical discectomy with prosthetic disc replacement / Squale.
Device: PICC implantation under fluoroscopy;Device: PICC Implantation under Sherlock System
Drug: FF/UMEC/VI (100/31.25/25) mcg;Drug: FF/UMEC/VI (100/62.5/25) mcg;Drug: FF/UMEC/VI (200/31.25/25) mcg;Drug: FF/UMEC/VI (200/62.5/25) mcg;Drug: FF/VI (100/25) mcg;Drug: FF/VI (200/25) mcg;Drug: Fluticasone/salmeterol (FSC);Drug: Albuterol/salbutamol;Device: ELLIPTA DPI;Device: DISKUS DPI;Device: METERED-DOSE INHALER (MDI)
Biological: Neulasta, B12019;Biological: Neulasta, B12019;Biological: Neulasta, B12019;Biological: Neulasta, B12019
Device: REMOGEN OMEGA;Device: Povidone
Other: 1 - Fermented dairy drink;Other: 2 - Acidified dairy drink
Drug: Setmelanotide;Drug: Placebo
Drug: Enstilar®
Drug: GL-0817;Drug: Hiltonol;Drug: Sargramostim;Drug: cyclophosphamide;Drug: Placebo
Dietary Supplement: IQP-AS-121
Drug: Fluvoxamine;Drug: BI 409306;Drug: BI 409306;Drug: Fluvoxamine;Drug: BI 409306;Drug: BI 409306;Drug: Fluvoxamine;Drug: BI 409306;Drug: BI 409306;Drug: Fluvoxamine;Drug: BI 409306;Drug: BI 409306
Drug: BI 695501;Drug: Humira
Device: IOL MINI WELL READY
Device: suprapubic tube ex 2 day;Device: suprapubic tube ex 5 day;Device: transurethral catheter ex 5 day
Drug: Ovaleap®
Drug: Placebo;Drug: Adalimumab
Drug: Placebo;Drug: M2951;Drug: M2951
Drug: Lanabecestat;Drug: Placebo
Drug: GNbAC1;Drug: Placebo
Behavioral: D-MCT;Behavioral: Health Training;Behavioral: D-MCT;Behavioral: Health Training;Behavioral: D-MCT;Behavioral: Health Training;Behavioral: D-MCT;Behavioral: Health Training
Drug: AL-335;Drug: Odalasvir;Drug: Simeprevir
Other: probiotic yoghurt;Other: chemically acidified milk;Drug: Arilin
Drug: Intranasal Esketamine;Drug: Intravenous Esketamine;Drug: Moxifloxacin;Drug: Oral Placebo;Drug: Intravenous Placebo;Drug: Intranasal Placebo
Drug: Octagam 10%;Other: Placebo
Procedure: Blood sample collection;Other: Assessment of signs of organ dysfunction
Drug: Pegylated Interferon (PEG-IFN) alfa-2a;Drug: Placebo;Drug: Ribavirin;Drug: Pegylated Interferon (PEG-IFN) alfa-2a;Drug: Placebo;Drug: Ribavirin;Drug: Pegylated Interferon (PEG-IFN) alfa-2a;Drug: Placebo;Drug: Ribavirin;Drug: Pegylated Interferon (PEG-IFN) alfa-2a;Drug: Placebo;Drug: Ribavirin
Device: aCRT ON;Device: aCRT OFF
Drug: Investigational Medical Product (IMP) administered in parent study
Device: Perceval valve;Device: other stented biological valve
Device: PS1;Device: PS2;Device: PS3
Drug: antibody ch14.18;Drug: GM-CSF;Drug: IL-2 i.v.;Drug: IL-2 s.c.;Drug: Retinoic acid;Drug: antibody ch14.18;Drug: GM-CSF;Drug: IL-2 i.v.;Drug: IL-2 s.c.;Drug: Retinoic acid;Drug: antibody ch14.18;Drug: GM-CSF;Drug: IL-2 i.v.;Drug: IL-2 s.c.;Drug: Retinoic acid;Drug: antibody ch14.18;Drug: GM-CSF;Drug: IL-2 i.v.;Drug: IL-2 s.c.;Drug: Retinoic acid
Drug: Belimumab;Drug: Rituximab;Drug: Placebo belimumab;Drug: Placebo rituximab
Drug: LGX818;Drug: MEK162;Drug: Nivolumab;Drug: Ipilimumab
Drug: ORGN001 (formerly ALXN1101)
Drug: Tanezumab
Drug: Omega-3 fatty acids;Other: Placebo
Drug: Batefenterol;Drug: Umeclidinium/ Vilanterol;Drug: Placebo
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Drug: sumanirole
Drug: ELC200 (carbidopa+levodopa+entacapone)
Drug: Semaglutide;Drug: Placebo (semaglutide)
Drug: Progesterone;Drug: Progesterone;Drug: Progesterone;Drug: Progesterone;Drug: Progesterone;Drug: Progesterone;Drug: Progesterone;Drug: Progesterone
Other: more meat and a vegetable oil rich in omega-3 fatty acids;Other: Babyfood with usual meat content and corn oil;Other: more meat and a vegetable oil rich in omega-3 fatty acids;Other: Babyfood with usual meat content and corn oil;Other: more meat and a vegetable oil rich in omega-3 fatty acids;Other: Babyfood with usual meat content and corn oil;Other: more meat and a vegetable oil rich in omega-3 fatty acids;Other: Babyfood with usual meat content and corn oil
Drug: insulin aspart;Drug: insulin detemir
Drug: Salmeterol 50mcg/ Fluticasone Propionate 500mcg;Drug: Salmeterol 50mcg/ Fluticasone Propionate 500mcg;Drug: Salmeterol 50mcg/ Fluticasone Propionate 500mcg;Drug: Salmeterol 50mcg/ Fluticasone Propionate 500mcg
Drug: Lubiprostone;Drug: Placebo
Biological: Thymoglobulin [Anti-thymocyte Globulin (rabbit)];Drug: Simulect (basliximab)
Biological: Secukinumab (AIN457);Biological: Placebo;Biological: Secukinumab (AIN457);Biological: Placebo;Biological: Secukinumab (AIN457);Biological: Placebo;Biological: Secukinumab (AIN457);Biological: Placebo
Drug: spironolactone;Drug: placebo
Drug: Dexrazoxane
Biological: aldesleukin;Biological: recombinant interferon alfa;Drug: fluorouracil
Other: metabolic assessment;Other: physiologic testing;Procedure: biopsy;Procedure: computed tomography;Procedure: conventional surgery;Procedure: magnetic resonance imaging;Procedure: management of therapy complications;Procedure: psychosocial assessment and care;Procedure: quality-of-life assessment;Radiation: radiation therapy
Procedure: Interrupted sutures;Procedure: Continuous sutures
Drug: tozadenant;Drug: placebo
Drug: Oxaliplatin 130 mg/m^2;Drug: Capecitabine 1000 mg/m^2;Drug: Bevacizumab 7.5 mg/kg;Drug: Placebo for bevacizumab 7.5 mg/kg;Drug: Oxaliplatin 85 mg/m^2;Drug: Leucovorin 200 mg/m^2;Drug: Fluorouracil 400 mg/m^2;Drug: Bevacizumab 5 mg/kg;Drug: Placebo for bevacizumab 5 mg/kg;Drug: Oxaliplatin 130 mg/m^2;Drug: Capecitabine 1000 mg/m^2;Drug: Bevacizumab 7.5 mg/kg;Drug: Placebo for bevacizumab 7.5 mg/kg;Drug: Oxaliplatin 85 mg/m^2;Drug: Leucovorin 200 mg/m^2;Drug: Fluorouracil 400 mg/m^2;Drug: Bevacizumab 5 mg/kg;Drug: Placebo for bevacizumab 5 mg/kg;Drug: Oxaliplatin 130 mg/m^2;Drug: Capecitabine 1000 mg/m^2;Drug: Bevacizumab 7.5 mg/kg;Drug: Placebo for bevacizumab 7.5 mg/kg;Drug: Oxaliplatin 85 mg/m^2;Drug: Leucovorin 200 mg/m^2;Drug: Fluorouracil 400 mg/m^2;Drug: Bevacizumab 5 mg/kg;Drug: Placebo for bevacizumab 5 mg/kg;Drug: Oxaliplatin 130 mg/m^2;Drug: Capecitabine 1000 mg/m^2;Drug: Bevacizumab 7.5 mg/kg;Drug: Placebo for bevacizumab 7.5 mg/kg;Drug: Oxaliplatin 85 mg/m^2;Drug: Leucovorin 200 mg/m^2;Drug: Fluorouracil 400 mg/m^2;Drug: Bevacizumab 5 mg/kg;Drug: Placebo for bevacizumab 5 mg/kg
Drug: Tarceva (erlotinib HCl, OSI-774)
Drug: azithromycin (Zithromax);Drug: placebo;Drug: azithromycin SR;Drug: placebo
Drug: MEDI4736 (durvalumab);Drug: Vinorelbine;Drug: Gemcitabine;Drug: Erlotinib;Drug: MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4);Drug: tremelimumab (anti-CTLA4)
Biological: rIX-FP;Biological: rIX-FP;Biological: rIX-FP;Biological: rIX-FP
Drug: LT-02;Drug: LT-02;Drug: Placebo;Drug: LT-02;Drug: LT-02;Drug: Placebo;Drug: LT-02;Drug: LT-02;Drug: Placebo;Drug: LT-02;Drug: LT-02;Drug: Placebo
Drug: Telmisartan 80 mg + hydrochlorothiazide 12.5 mg;Drug: Amlodipine 10 mg + hydrochlorothiazide 12.5 mg
Drug: CEP-701;Drug: high-dose cytarabine;Drug: Mitozantrone, Etoposide, Cytarabine (combination Chemotherapy)
Drug: ABT-199;Other: Placebo;Drug: ABT-199;Other: Placebo;Drug: ABT-199;Other: Placebo;Drug: ABT-199;Other: Placebo
Drug: clopidogrel;Drug: PRT060128;Drug: clopidogrel;Drug: PRT060128;Drug: clopidogrel;Drug: PRT060128;Drug: clopidogrel;Drug: PRT060128
Drug: Bosentan
Drug: ibandronate, calcium and  vitamin D;Drug: placebo,calcium and vitamin D
Drug: sitagliptin;Drug: glimepiride
Procedure: PEEP titration
Drug: Moxifloxacin (Avelox, BAY12-8039)
Drug: satavaptan (SR121463B)
Biological: MEDI5117;Biological: MEDI5117 Placebo
Drug: Gestodene/EE Patch (BAY86-5016);Drug: Gestodene/EE Patch (BAY86-5016);Drug: Gestodene/EE Patch (BAY86-5016)
Biological: BAX 326;Biological: BeneFIX
Device: Deep brain stimulation of the internal globus pallidus
Drug: BG00012;Drug: Placebo;Drug: BG00012;Drug: Placebo;Drug: BG00012;Drug: Placebo;Drug: BG00012;Drug: Placebo
Procedure: Positioning and plexus anesthesia
Drug: oxcarbazepine
Drug: Octreotide LAR (Long-acting release);Drug: Placebo
Drug: VIVITROL 380 mg;Drug: Placebo for VIVITROL 380 mg;Drug: VIVITROL 380 mg;Drug: Placebo for VIVITROL 380 mg;Drug: VIVITROL 380 mg;Drug: Placebo for VIVITROL 380 mg;Drug: VIVITROL 380 mg;Drug: Placebo for VIVITROL 380 mg
Drug: insulin degludec;Drug: insulin degludec;Drug: insulin degludec;Drug: insulin degludec
Device: DEBlue stent vs. Cypher stent
Biological: botulinum toxin Type A;Drug: Placebo;Biological: botulinum toxin Type A;Drug: Placebo;Biological: botulinum toxin Type A;Drug: Placebo;Biological: botulinum toxin Type A;Drug: Placebo
Drug: Velcade (Bortezomib);Drug: Thalidomide;Drug: Dexamethasone
Drug: valsartan;Drug: lisinopril;Drug: valsartan;Drug: lisinopril;Drug: valsartan;Drug: lisinopril;Drug: valsartan;Drug: lisinopril
Drug: Parathyroid Hormone (PTH) (1-84);Drug: Parathyroid Hormone (PTH) (1-84);Drug: Parathyroid Hormone (PTH) (1-84);Drug: Parathyroid Hormone (PTH) (1-84)
Drug: Sorafenib (Nexavar, BAY43-9006)
Procedure: Excision plus hyaluronic acid gel;Procedure: Excision only;Procedure: Excision plus hyaluronic acid gel;Procedure: Excision only
Drug: Irbesartan;Drug: placebo;Drug: Irbesartan;Drug: placebo;Drug: Irbesartan;Drug: placebo;Drug: Irbesartan;Drug: placebo
Drug: Placebo;Drug: CP690,550;Drug: CP-690,550;Drug: Placebo;Drug: CP690,550;Drug: CP-690,550;Drug: Placebo;Drug: CP690,550;Drug: CP-690,550;Drug: Placebo;Drug: CP690,550;Drug: CP-690,550
Procedure: AV nodal ablation;Drug: Medical Ventricular Rate Control
Drug: methotrexate;Radiation: radiotherapy
Drug: Atorvastatin;Drug: Placebo
Drug: Cinacalcet;Drug: Placebo
Drug: Cebranopadol;Drug: Morphine Prolonged Release
Drug: Ziprasidone Hydrochloride;Drug: Placebo
Drug: Zonisamide;Drug: Placebo;Drug: Zonisamide;Drug: Placebo;Drug: Zonisamide;Drug: Placebo;Drug: Zonisamide;Drug: Placebo
Radiation: total-body irradiation;Drug: fludarabine phosphate;Drug: cyclosporine;Drug: mycophenolate mofetil;Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;Biological: donor lymphocytes;Procedure: peripheral blood stem cell transplantation;Other: laboratory biomarker analysis
Drug: GSK1278863;Other: Placebo;Drug: GSK1278863;Other: Placebo;Drug: GSK1278863;Other: Placebo;Drug: GSK1278863;Other: Placebo
Biological: Bezlotoxumab;Drug: Placebo
Drug: Octreotide;Drug: Placebo;Drug: Everolimus;Drug: Octreotide;Drug: Placebo;Drug: Everolimus;Drug: Octreotide;Drug: Placebo;Drug: Everolimus;Drug: Octreotide;Drug: Placebo;Drug: Everolimus
Drug: Triptorelin Pamoate (Pamorelin® LA 11.25 mg)
Drug: Palonosetron;Drug: Palonosetron;Drug: Ondansetron;Drug: Placebo to Ondansetron;Drug: Placebo to Ondansetron;Drug: Placebo to Palonosetron;Drug: Palonosetron;Drug: Palonosetron;Drug: Ondansetron;Drug: Placebo to Ondansetron;Drug: Placebo to Ondansetron;Drug: Placebo to Palonosetron;Drug: Palonosetron;Drug: Palonosetron;Drug: Ondansetron;Drug: Placebo to Ondansetron;Drug: Placebo to Ondansetron;Drug: Placebo to Palonosetron;Drug: Palonosetron;Drug: Palonosetron;Drug: Ondansetron;Drug: Placebo to Ondansetron;Drug: Placebo to Ondansetron;Drug: Placebo to Palonosetron
Biological: LY2127399;Drug: Placebo
Drug: Cetuximab
Biological: autologous bone marrow-derived cells
Drug: taranabant;Drug: placebo
Drug: TMC435;Drug: Pegylated interferon alpha-2a;Drug: Ribavirin;Drug: TMC435;Drug: Pegylated interferon alpha-2a;Drug: Ribavirin;Drug: TMC435;Drug: Pegylated interferon alpha-2a;Drug: Ribavirin;Drug: TMC435;Drug: Pegylated interferon alpha-2a;Drug: Ribavirin
Drug: fosamprenavir (GW433908);Drug: ritonavir;Drug: fosamprenavir (GW433908);Drug: ritonavir;Drug: fosamprenavir (GW433908);Drug: ritonavir;Drug: fosamprenavir (GW433908);Drug: ritonavir
Drug: Ramucirumab;Drug: Pembrolizumab
Drug: Esomeprazole 40 mg;Drug: Esomeprazole 20 mg;Drug: Placebo;Drug: Esomeprazole 40 mg;Drug: Esomeprazole 20 mg;Drug: Placebo;Drug: Esomeprazole 40 mg;Drug: Esomeprazole 20 mg;Drug: Placebo;Drug: Esomeprazole 40 mg;Drug: Esomeprazole 20 mg;Drug: Placebo
Dietary Supplement: NutriDrink;Dietary Supplement: Placebo
Drug: pramipexole
Drug: ponatinib;Drug: imatinib (Gleevec/ Glivec);Drug: ponatinib;Drug: imatinib (Gleevec/ Glivec);Drug: ponatinib;Drug: imatinib (Gleevec/ Glivec);Drug: ponatinib;Drug: imatinib (Gleevec/ Glivec)
Procedure: laboratory analysis;Procedure: laboratory analysis;Procedure: laboratory analysis;Procedure: laboratory analysis
NULL
Drug: Cetuximab;Procedure: Liver resection;Drug: Cetuximab and FOLFIRI;Drug: Cetuximab and FOLFOX
NULL
Drug: esomeprazole 20 mg
NULL
Drug: Mesalazine - TID 1000 mg;Drug: Mesalazine - TID 2x 500 mg
Biological: alemtuzumab;Drug: cyclophosphamide;Drug: fludarabine phosphate;Drug: mitoxantrone hydrochloride
Drug: Glucagon hydrochloride (GlucaGen®);Drug: NaCl 0.9%
Drug: MP4OX;Drug: MP4OX;Drug: Ringers Lactate solution
Drug: Canakinumab 150 mg;Drug: Triamcinolone acetonide 40 mg;Drug: Placebo to canakinumab;Drug: Placebo to triamcinolone acetonide;Drug: Canakinumab 150 mg;Drug: Triamcinolone acetonide 40 mg;Drug: Placebo to canakinumab;Drug: Placebo to triamcinolone acetonide;Drug: Canakinumab 150 mg;Drug: Triamcinolone acetonide 40 mg;Drug: Placebo to canakinumab;Drug: Placebo to triamcinolone acetonide;Drug: Canakinumab 150 mg;Drug: Triamcinolone acetonide 40 mg;Drug: Placebo to canakinumab;Drug: Placebo to triamcinolone acetonide
Drug: LDE225;Drug: BKM120
Drug: sirolimus
Drug: bosentan;Drug: bosentan;Drug: bosentan;Drug: bosentan
Drug: Teriparatide;Drug: Placebo;Dietary Supplement: Calcium supplementation;Dietary Supplement: Vitamin D supplementation;Drug: Teriparatide;Drug: Placebo;Dietary Supplement: Calcium supplementation;Dietary Supplement: Vitamin D supplementation;Drug: Teriparatide;Drug: Placebo;Dietary Supplement: Calcium supplementation;Dietary Supplement: Vitamin D supplementation;Drug: Teriparatide;Drug: Placebo;Dietary Supplement: Calcium supplementation;Dietary Supplement: Vitamin D supplementation
Drug: bendamustine hydrochloride;Drug: mitoxantrone hydrochloride
Drug: AMG 479;Drug: Placebo;Drug: AMG 479;Drug: gemcitabine
Behavioral: Progressive strength training
Drug: Linagliptin;Drug: Empagliflozin;Drug: Placebo
Device: barrier membrane;Device: MembraGel;Other: Bio-Gide® membrane
Device: Sepraspray
Radiation: Fab-fragment of Anti-human CD4
Drug: Repinotan HCl (BAYX3702);Drug: Placebo
Other: Interleukin 28B testing;Other: Interleukin 28B testing;Other: Interleukin 28B testing;Other: Interleukin 28B testing
Drug: Docetaxel;Drug: Ganetespib;Drug: Docetaxel;Drug: Ganetespib;Drug: Docetaxel;Drug: Ganetespib;Drug: Docetaxel;Drug: Ganetespib
Drug: GW870086 2.0%;Drug: GW870086 0.2%;Drug: FP 0.05%;Drug: Placebo;Drug: GW870086 2.0%;Drug: GW870086 0.2%;Drug: FP 0.05%;Drug: Placebo;Drug: GW870086 2.0%;Drug: GW870086 0.2%;Drug: FP 0.05%;Drug: Placebo;Drug: GW870086 2.0%;Drug: GW870086 0.2%;Drug: FP 0.05%;Drug: Placebo
Drug: Succinylcholine;Drug: Rocuronium 0,3;Drug: Rocuronium 0,6;Drug: Succinylcholine;Drug: Rocuronium 0,3;Drug: Rocuronium 0,6;Drug: Succinylcholine;Drug: Rocuronium 0,3;Drug: Rocuronium 0,6;Drug: Succinylcholine;Drug: Rocuronium 0,3;Drug: Rocuronium 0,6
Drug: Placebo;Drug: Abiraterone acetate;Drug: Prednisone/prednisolone;Drug: Placebo;Drug: Abiraterone acetate;Drug: Prednisone/prednisolone;Drug: Placebo;Drug: Abiraterone acetate;Drug: Prednisone/prednisolone;Drug: Placebo;Drug: Abiraterone acetate;Drug: Prednisone/prednisolone
Drug: turoctocog alfa pegol
Drug: capecitabine;Drug: oxaliplatin;Drug: capecitabine;Drug: oxaliplatin
Dietary Supplement: test coffee;Dietary Supplement: control coffee
Drug: mirabegron 25 mg;Drug: mirabegron 50 mg;Drug: solifenacin 5 mg;Drug: solifenacin 10 mg;Drug: mirabegron 25 mg matching placebo;Drug: mirabegron 50 mg matching placebo;Drug: solifenacin 5 mg matching placebo;Drug: solifenacin 10 mg matching placebo
Drug: Budesonide;Drug: Budesonide;Drug: Budesonide;Drug: Budesonide
Drug: LBH589;Drug: LBH589;Drug: LBH589;Drug: LBH589
Biological: LMB-9 immunotoxin
Drug: [S,S]-Reboxetine + Pregabalin;Drug: Pregabalin
Drug: Galcanezumab;Drug: Placebo
Drug: Zoledronic Acid;Drug: Zoledronic Acid;Drug: Zoledronic Acid;Drug: Zoledronic Acid
Drug: carboplatin;Drug: pegylated liposomal doxorubicin hydrochloride
Drug: MEK162, MEK inhibitor; oral;Drug: Physician's choice chemotherapy
Drug: olaparib;Drug: abiraterone acetate
NULL
Drug: Dronedarone (SR33589);Drug: placebo
Procedure: Spiroergometry
Drug: mFOLFOX6 + BIBF 1120;Drug: mFOLFOX6+placebo
Procedure: Aortic Valve Replacement surgery
Drug: Insulin Peglispro;Drug: Insulin Glargine
Device: Locomotor training using a robotic device;Device: Locomotor training using a robotic device;Device: Locomotor training using a robotic device;Device: Locomotor training using a robotic device
Drug: peginesatide;Drug: Epoetin alfa or Epoetin beta;Drug: peginesatide;Drug: Epoetin alfa or Epoetin beta;Drug: peginesatide;Drug: Epoetin alfa or Epoetin beta;Drug: peginesatide;Drug: Epoetin alfa or Epoetin beta
Drug: BAY85-3934;Biological: Darbepoetin alfa
Drug: Saizen® solution for injection (referred as Saizen®);Drug: Saizen® solution for injection (referred as Saizen®);Drug: Saizen® solution for injection (referred as Saizen®);Drug: Saizen® solution for injection (referred as Saizen®)
Biological: Ravulizumab;Biological: Eculizumab
Drug: ifosfamide;Drug: pegylated liposomal doxorubicin hydrochloride
Drug: ITCA 650 (Exenatide in osmotic mini pump)
Drug: Oralgen;Drug: grass pollen extract
Drug: Xarelto (Rivaroxaban, BAY59-7939);Drug: Xarelto (Rivaroxaban, BAY59-7939);Drug: Xarelto (Rivaroxaban, BAY59-7939);Drug: Xarelto (Rivaroxaban, BAY59-7939);Drug: Enoxaparin/Vitamin K-Antagonist
Procedure: Reduced Intensity Conditioning Stem Cell Transplantation
Behavioral: Optimal Diet;Dietary Supplement: VSL#3®;Dietary Supplement: AISA-5203-L;Dietary Supplement: Argan oil
Procedure: Routine hilar lymphadenectomy;Procedure: Routine hilar lymphadenectomy;Procedure: Routine hilar lymphadenectomy;Procedure: Routine hilar lymphadenectomy
Behavioral: exercise and relaxation
Drug: tobramycin;Drug: tobramycin;Drug: tobramycin;Drug: tobramycin;Drug: tobramycin;Drug: tobramycin;Drug: tobramycin;Drug: tobramycin
Drug: placebo;Drug: BIBF 1120;Drug: placebo;Drug: BIBF 1120;Drug: placebo;Drug: BIBF 1120;Drug: placebo;Drug: BIBF 1120
Procedure: leukocyte depletion of whole blood;Other: Leukocyte filtration/Depletion
Drug: Lanreotide autogel 120 mg
Other: Soluble Coffee
Drug: Acetylsalicylic Acid (Aspirin, BAYE4465);Drug: Ibuprofen;Drug: Placebo
NULL
Radiation: Radiation therapy
Drug: Gantacurium Chloride for Injection (AV430A)
Drug: sabarubicin
Drug: NOX-A12;Drug: NOX-A12;Drug: Filgrastim;Drug: NOX-A12 in combination with Filgrastim
Drug: Tobramycin Inhalation Powder;Drug: Tobramycin Solution for Inhalation;Drug: Tobramycin Inhalation Powder;Drug: Tobramycin Solution for Inhalation;Drug: Tobramycin Inhalation Powder;Drug: Tobramycin Solution for Inhalation;Drug: Tobramycin Inhalation Powder;Drug: Tobramycin Solution for Inhalation
Drug: sotrastaurin (Dose 1) + tacrolimus + standard of care medications;Drug: sotrastaurin (Dose 2) + tacrolimus + standard of care medications;Drug: sotrastaurin (Dose 3) + tacrolimus + standard of care medications;Drug: mycophenolic acid + tacrolimus + standard of care medications
Device: HM on;Device: HM Off
Procedure: conventional embolectomy/thrombectomy;Procedure: embolectomy/thrombectomy with controlled reperfusion
Procedure: Bilateral approach for Laminoplasty;Procedure: Unilateral approach for laminoplasty;Procedure: Subperiosteal approach for foraminotomy;Procedure: Transmuscular approach for foraminotomy
Drug: insulin degludec;Drug: insulin degludec;Drug: insulin degludec;Drug: insulin degludec
Drug: VB-201;Drug: VB-201;Other: Placebo
Drug: GW842166
Drug: CGM097
Procedure: Percutaneous Coronary Intervention;Procedure: BMNC therapy
Biological: Albiglutide weekly injection;Biological: Placebo weekly injection;Biological: Insulin
Drug: Cabazitaxel (XRP6258);Drug: Prednisone (or Prednisolone);Drug: Cabazitaxel (XRP6258);Drug: Prednisone (or Prednisolone);Drug: Cabazitaxel (XRP6258);Drug: Prednisone (or Prednisolone);Drug: Cabazitaxel (XRP6258);Drug: Prednisone (or Prednisolone)
Device: Biolimus-eluting stent implantation
NULL
Device: brain stimulation;Device: SHAM
Drug: Atomoxetine
Device: XIENCE V®/ XIENCE PRIME™;Device: CYPHER SELECT;Device: XIENCE V®/ XIENCE PRIME™;Device: CYPHER SELECT;Device: XIENCE V®/ XIENCE PRIME™;Device: CYPHER SELECT;Device: XIENCE V®/ XIENCE PRIME™;Device: CYPHER SELECT
Behavioral: Smoking;Behavioral: Smoking
Biological: GC1008;Biological: GC1008;Biological: GC1008;Biological: GC1008
Device: Endovascular abdominal aortic aneurysm repair
Drug: POL7080
NULL
Drug: Interleukin-2;Drug: Ipilimumab
Drug: Valsartan;Other: Placebo
Drug: LY900014;Drug: Insulin Lispro
Drug: quetiapine;Drug: escitalopram
Dietary Supplement: mistletoe extract
Biological: MenACWY-CRM197 (two doses);Biological: MenC;Biological: PCV7;Biological: DTPa-IPV-HepB-Hib;Biological: MenACWY-CRM197 (one dose);Biological: MenACWY-CRM197 (two doses);Biological: MenC;Biological: PCV7;Biological: DTPa-IPV-HepB-Hib;Biological: MenACWY-CRM197 (one dose);Biological: MenACWY-CRM197 (two doses);Biological: MenC;Biological: PCV7;Biological: DTPa-IPV-HepB-Hib;Biological: MenACWY-CRM197 (one dose);Biological: MenACWY-CRM197 (two doses);Biological: MenC;Biological: PCV7;Biological: DTPa-IPV-HepB-Hib;Biological: MenACWY-CRM197 (one dose)
Drug: Ovarian stimulation in a GnRH-antagonist protocol
NULL
Intervention 1: Patient with sepsis, tissue sampling of palatine tonsils Intervention 2: Patients with chronic tonsillitis, tissue sampling of palatine tonsils Intervention 3: Patients with tonsil hyperplasia, tissue sampling of palatine tonsils
Intervention 1: Patients with Gastrointestinal Stromal Tumors undergoing tyrosine kinase inhibitor treatment will be assessed regarding progression-free survival and overall survival within 2 years using the standard response criteria, in particular Response Evaluation Criteria In Solid Tumors, the WHO criteria for response, the tumor lesion volume as well as tumor density (according to Choi). Intervention 2: Patients with Gastrointestinal Stromal Tumors undergoing  tyrosine kinase inhibitor treatment will be assessed regarding progression-free survival and overall survival within 2 years using the response criteria, in particular tumor lesion iodine uptake normalised to the aorta and tumor lesion iodine uptake normalised to the portal vein.
Intervention 1: Intraindividual comparison of 3D transesophageal echocardiography measurements and MSCT (multidetector computed tomography) measurements for the selection of the appropriate valve prosthesis before transvascular transcatheter aortic valve replacement (TAVR)
Behavioral: Discharge home
Intervention 1: Application of TXA for given indications such as severe trauma, severe gynecological bleeding, GI bleeding, TE rebleeding.<br>We analyze emergency medical protocols for appropriate applications.<br>To get indicators for other potential indications, we match possible indications with clinical laboratory data and medical reports.
Intervention 1: Over a period of 6 weeks, the intervention group participants will listen to their individualized music playlist through headphones every other day for 20 minutes in the presence of employees of the nursing home or project staff. Observation of behavior will be conducted by the project staff every other week before, during and after the music intervention. Intervention 2: The control group receives standard care. The observation of behavior will be conducted with the same frequency and duration as in the intervention group.
Intervention 1: Patients with diagnosed arterial hypertension. Patients undergo measurements of pulse wave velocity and peripheral blood pressure as well as ultrasound elastography of the aorta. Intervention 2: Healthy volunteers. Volunteers undergo measurements of pulse wave velocity and peripheral blood pressure as well as ultrasound elastography of the aorta.
Intervention 1: The following parameters will be included in the individualized pharmacotherapeutical risk information:<br> - genetical analysis (CYP2C9, CYP2C19, VCORC1)<br>- drug- drug interaction test<br>- liver values and other lab values<br><br>There will be no given direction to change the drug therapy. The doctor can act as he thinks is best for the patient. Every 3 month (3 times ) there will be consultations with the patient, where the patients will be ask about their general health. The patients will be ask the following questions, just to list a few:<br>-  number of sick certifcates<br>- number of specialist's referral<br>- number of admissions to a hosital<br>- accidents (traffic, in the house, at work,....)<br>- operations<br>- invasive examination (e.g. catheter)<br>- allergic reactions<br>- headache<br>- nausea<br>-......... Intervention 2: Patients that get the standardized risk information will get informed in detail about their liver values and other values, that were measured in the lab. Also they will get detailed information again about the meaning of oral anticoagulation. The treatment will be according to current medical standards including additional standardized information on risk factors for adverse drug effects. Every 3 month ( 3 times altogteher) the patients are ask for their health status. the following paramters are being documented:<br>-  number of sick certifcates<br>- number of specialist's referral<br>- number of admissions to a hosital<br>- accidents (traffic, in the house, at work,....)<br>- severe adverse drug reactions <br>- Number of hospital admissions due to adverse drug effects<br>- Number of specialist consultations due to problems in drug therapy<br>- Number of medication changes during obsevation period<br>- etc. ....
Intervention 1: This prospective descriptive observational study evaluates the prevalence of simultaneous outletimpingement in patients with calcifying tendinitis, considering either the pre- and postoperative x-rays and also standardized intraoperative views from the shoulder arthroscopy of the next 60 patients with calcifying tendinitis which proved refractory to conservative treatment and who will be treated with shoulder arthroscopy in our clinic according to our standard treatment. The intraoperative subacromial views will be taken before and after the (as performed as a standard procedure in our clinic in these patients) arthroscopic subacromial decompression.<br>For an evaluation of the outcome of our patients, they will get to fill out the established constant score-patient-questionnaire for self-evaluation; 3-6 months after the operation, we will do a telephone interview using the same questionnaire. In addition, we will evaulate the radiologic extent of removal of the calcification when intraoperative x-ray is used. We use intraoperative x-ray as a standard procedure during operations for calcifying tendinitis to be able to remove as much of the calcification as possible and to be able to definitely find and open all the calcifications. <br><br>50 of the patients that we planned for the study had complete data sets. <br>During the study, we decided to add a second follow-up after a longer period of 1-2 years to increase the validity of the clinical outcome.
Intervention 1: 150-300mg / m bexarotene daily per os for at least 24 weeks
Intervention 1: Temporary restoration made of Protemp 4 Intervention 2: Temporary restoration made of Luxatemp® Automix Plus<br>Reference data, retrospective comparison
Intervention 1: Patient with cancer pain, Matrixstimulation, 4 Hz, 5 Minutes, Stimulation twice a day (morning and evening) on three consecutive days (day 1-3).
Intervention 1: Monitoring of patients with scheduled transcatheter closure of Secundum Atrial Septal Defects (ASD II) with Ceraflex-ASD-Occluder
Intervention 1: Single arm. Interventions: Questionnaires for patients and treating physicians. Collection of 10 mL EDTA blood (during routine checks) for resistance analysis
Intervention 1: Test group: participants get grades in the courses of orthodontics- via the e-larning based portal Itunes U Intervention 2: Control group: participants receive the dichotomous test sheet and additionally grades in secret
Intervention 1: use of gcs (graduated compression stockings) Intervention 2: no use of gcs
Intervention 1: Risk-adjusted analysis of standardized data from hospital reimbursement claims (§21-Datatset according to the German Law of Hospital Reimbursement (Krankenhausentgeltgesetz)) of patients with sepsis, severe sepsis and septic shock of participating hospitals. The quality reports for analyses are created every three months for all participating hospitals allowing individual case analyses, analyses according to departments, and anonymous benchmarking with all other participating hospitals and the German average.
Intervention 1: initial vitrectomy with ILM-peeling with intraoperative andministration of Ranibizumab 0,5 mg intravitreally. After vitrectomy, 2 further injections of 0,5 mg Ranibizumab every 4 weeks will be performed, according to the label of Ranibizumab (Lucentis ®). After the first 3 obligatory treatments with Ranibizumab, examination will be performed every 4 weeks. Further injections will be given, according to the label of Ranibizumab (Lucentis ®), if indicated. Intervention 2: Three initial injections of 0,5 mg Ranibizumab every 4 weeks will be performed, according to the label of Ranibizumab (Lucentis ®). After the first 3 obligatory treatments with Ranibizumab, examination will be performed every 4 weeks. Further injections will be given, according to the label of Ranibizumab (Lucentis ®), if indicated
Intervention 1: Intervention phase: Use of a digital paediatric drug information system,<br>participation to regular paediatric-pharmacological quality circles,<br>stimulated spontaneous reporting of adverse drug reactions and medication errors in outpatient paediatricians, psychiatrists and general practitioners Intervention 2: Control phase
Intervention 1: Intake of Eusano formulation 3 capsules per day
Intervention 1: The ACROSSS Study includes patients who have sufferred from a myocardial infarction, a stroke or a transient ischemic attack. The aim of the study is to answer two questions: First, to investigate whether the acute event has an impact on the patients´ sleep like worse sleep quality or taking a nap more often. Second, to investigate which factors might have triggered the acute event, e.g. a nap taken shortly before or the intake of certain drugs.<br><br>The following investigations will be carried out:<br><br>T1: First contact with the participants who have left the intensive care unit <br>- questionnaires on sleep characteristics and sleep behaviour in the last 4 weeks before the index event<br>- case-crossover questionnaire<br>- questionnaire on comorbidities and confounders<br>- questionnaire on functional restrictions<br>- sleep apnea measurement (using the device Apnea Link)<br><br>T2: 3 months after the index event<br>- questionnaires on sleep characteristics and sleep behaviour in the last 4 weeks<br>- questionnaire on functional restrictions<br>- drug history<br>- measurement of sleep behaviour and daytime activity (using the device SOMNOwatch)<br>- assessment of vital status via questionnaire (further myocardial infarction / stroke / TIA / death)<br><br>T3: 1 year after the index event<br>- questionnaires on sleep characteristics and sleep behaviour in the last 4 weeks<br>- questionnaire on functional restrictions<br>- drug history<br>- measurement of sleep behaviour and daytime activity (using the device SOMNOwatch)<br>- assessment of vital status via questionnaire (further myocardial infarction / stroke / TIA / death)<br><br>T4: about 5 years after the index event<br>- assessment of vital status including research on cause of death
Biological: Pembrolizumab;Drug: Axitinib;Drug: Sunitinib
Drug: deflazacort;Drug: placebo
Intervention 1: only one arm since study is an observational study.<br>All patients with ARDS and a lung CT scan can be recruited into the  study. Automatic and manual lung CT analyses are performed and results compared.
Intervention 1: controlled diet according to 20% energy fom fat of consumed food, as well as isoflavones following placebo Intervention 2: controlled diet according to 40% energy fom fat of consumed food, as well as isoflavones following placebo
Intervention 1: In Patients, undergoing operative stabilization of the Patella before and after operative treatment a dynamic MRI of the knee joint, determining patellorfemoral kinematics will be carried out. Intervention 2: Healthy people with a dynamic MRI of the knee joint, determining patellorfemoral kinematics will be carried out.
Drug: Pazopanib;Drug: 5-FU, Oxaliplatin, Leukovorin (FLO)
Intervention 1: Based on a review of the literature and a manual that was developed in a former study, a training will be developed that enables teamleaders of rehabilitation clinics to act as team coaches in their teams. All participating teamleaders wil receive training, which will be evaluated by a questionnaire and interviews. They will apply the trained coaching tools in their teams. Members of the teams will be observed and questioned (by interviews and questionnaires) regarding teamwork parameters in order to measure the coachings' effects and mechanisms of change.
Intervention 1: PVP-Hypericin instillation (225µg Hypericin) for 30+5 minutes, subsequently cystoscopy with white light followed by cystoscopy with blue light
Intervention 1: just manual mask ventilation Intervention 2: mask ventilation via anesthesia machine
Intervention 1: We will include 20 multiple sclerosis patients that are planned for alemtuzumab therapy in our study. <br>For one year we will analyze monthly additional lab parameters during the mandatory blood drawls.
Intervention 1: Inervention group (IG) with Eksoskeltt (Ekso Bionics): 45 minutes daily training from monday to friday for three weeks Intervention 2: Control group (CG): 45 minutes daily training from monday to friday for three weeks in conventional physiotherapy programm which includes fasclitation, trunc controll training, at least 20min walking with personal and/or devices aid (with the exception of Ekso)
Intervention 1: topical 3% polidocanol solution, one time application to the skin as spray, about 1ml in total; histamine prick (10mg/ml), 40 cowhage spicules rubbed on the skin for 40 seconds Intervention 2: placebo, one time application to the skin as spray, about 1ml in total; histamine prick (10mg/ml), 40 cowhage spicules rubbed on the skin for 40 seconds
Intervention 1: Study participants receive successively the possibility to use current noise suppression NR2 and compare this to NR3 SpatialNR. There is no comparison with other Groups of noise Suppression algorithms.<br>An intra-individual comparison will be performed.
Device: Thrombectomy;Other: Best medical care
Intervention 1: Cross over design. After baseline measurement of the expiratory flow, the flow will be limited in two steps (ca. 30% and ca. 60%; 3 min. each; randomised sequence). Intervention 2: see Arm 1
Intervention 1: Assessment of Overall Survival (OS) of all adult patients with a first histological diagnosis of diffuse low grade gliomas (DLGG) who were treated by either stereotactic biopsy or resection at the University Medical Center Freiburg between 2004 and 2012.
Intervention 1: The lifetime stress burden should be studied in individuals with subjective cognitive impairment, mild cognitive impairment, and mild to moderate Alzheimer's dementia. The study will cover various types of stress across lifespan, including occupational stress (Fragebogen zu Intensität und Tätigkeitsspielraum, FIT), stress-associated personality traits (EPQR-K, neuroticism), incriminating life events (Life Events Checklist (LEC), as well as neglect and abuse experiences childhood (Childhood Trauma Questionnaire; CTQ). Cognition at the time of completing the questionnaires is recorded using the Clinical Dementia Rating Scale (CDR), Shulman´s clock drawing test and Consortium to Establish a Registry for Alzheimer's Disease (CERAD). In addition, routine clinical data such as CSF-derived dementia markers are also used in the study. Furthermore, mental, social and physical activities carried out over the lifespan are recorded and their connection to cognition are analyzed Intervention 2: The relatives of the participants are recruited as a cognitively healthy control group. The control group completes the same questionnaires as the patient group. To rule out cognitive deficits, participants are asked if they have noticed subjective cognitive deficits and the Shulman's clock drawing test is completed. In addition, medical conditions that could influence cognition are requested.
Diagnostic Test: QFR and iFR
Intervention 1: After tumor excision wound treatment with Hyalomatrix (Anika Therapeutics S.r.l) followed by autologous skin graft Intervention 2: After tumor excision open wound treatment with Aqaucel (Convatec) followed by autologous skin graft
Intervention 1: mobility program: monitored balancetraining in sitting and standing, walking on spot or in patients room, training sit to stand for a maximum of 30 min, 3-5 times/week, 2 weeks additionally to standard therapy Intervention 2: endurance training with a bedside-ergometer for a maximum of 30 min., 3-5 times/week, 2 weeks additionally to standard therapy
Other: Perfusion-CT
Intervention 1: Assessment of physical performance (power, gait analysis, sit-to-stand transfer, grip strength, leg extension strength, balance) exposed to 15°C and 25°C in randomized order. Assessment of quality of life, cognition, depression, nutritional status, and thermal well-being by questionnaires. Assessment of physical activity by body-worn sensors and questionnaire. Assessment of muscle mass (thigh) by MRI. Blood samples (inflammatory markers) are taken at normal room temperature.
Drug: Pazopanib plus Gemcitabine;Drug: Pazopanib
Intervention 1: We recruite thirty consecutive patients consulting our PCIW. During the first or second session, the therapist informes the patient about the study. If the patient gives written informed consent, he is handed out a questionnaire which he should fill in within a week. The questionnaire containes the  Work-Ability-Index Kurzform (WAI), Patient-Health-Questionnaire (PHQ), SF-12 (Short Form health questionnaire), Maslach-Burnout-Inventory (MBI-GS-D), and the Irritation Scale (IS). Diagnoses, medication, smoking status and BMI are obtained and documented by the therapist. To measure HRV, the patient receives a stingray and a one channel ECG device (eMotion Faros 180°, Mega Electronic) and he is shown how to use it. He is handed out the salivettes for measurement of cortisol in the saliva and is again shown how to use it. ECG measurement should start in the evening around 18 o'clock. Saliva is taken on the following day at 0, 15, 30, 45, 60 min., 6 and 8 hours after awakening and at bed time. At this day in the evening, the stingray is taken off. <br>If indicated, the patient receives a short time therapy. It contains the following topics: identification of problematic schemes, focussing on one of them and working on alternative strategies; identification of ressources and strengthening of them; strenghthening of self efficacy by promoting sports and relaxation training. The second measurement (after the intervention) is done only in patients who received at least four sessions and is analogous to the first. Three months after intervention the patient is sent the same questionnaire again and he is contacted by telephone to remember to fill in the questionnaire.
Drug: Bortezomib
Intervention 1: Treatment group: Patients with Social Phobia who got 25 sessions cognitive therapy à 50 minutes according to the manual of Stangier, Clark and Ehlers (2006) between the first and the second measuring time. At three measuring time (before therapy, after, therapy, 6-month-follow-up), the subjective and psychoneuroendrocrinologically stress response during the Trier Social Stress Test (Kirschbaum, Pirke, & Hellhammer, 1993) was investigated. Intervention 2: Waitlist control group: Patients with Social Phobia who got no intervention between the first and the second measuring time. At three measuring time (before wait time, after wait time, 6-month-follow-up), the subjective and psychoneuroendrocrinologically stress response during the Trier Social Stress Test (Kirschbaum, Pirke, & Hellhammer, 1993) was investigated. Intervention 3: Health controls: Healthy participants who got no intervention between the first and the second measuring time. At three measuring times (pre, after 4-6 month, 6-month-follow-up), the subjective and psychoneuroendrocrinologically stress response during the Trier Social Stress Test (Kirschbaum, Pirke, & Hellhammer, 1993) was investigated.
Intervention 1: Members of statutory health insurance between 25 and 50 years living in Bavaria are invited to participate in the study. <br>Based on a short questionnaire on their family history of colorectal cancer (CRC), which is a simplified version of the Amsterdam and Bethesda criteria, participants are classified as potential risk carrier or as risk free.  <br>Participants with a family history of CRC can decide to undergo an iFOBT (fecal immunochemical test), a screening colonoscopy, or deferring further actions to a later point in life.<br>Participants in arm 1 are study participants with a family history of CRC who decide for one of the proposed screening measures. Intervention 2: Participants between 25 and 50 years living in Bavaria without family history of CRC Intervention 3: In arm 3, the incidence of CRC in members of statutory health insurance companies between 25 and 50 years of age living in Bavaria who do not participate in the study will be monitored through health administrative databases.
Drug: Fulvestrant
Drug: palbociclib;Drug: trastuzumab;Drug: pertuzumab;Drug: letrozole;Drug: Anastrozole;Drug: Exemestane;Drug: Fulvestrant
Esketamine group; 167 participantes: Open-label induction phase: Direct entry participants start at a dose of 56 mg on Day 1. From Day 4 to 15, dose may be adjusted per protocol at investigator’s discretion based on efficacy and/or tolerability; Optimization Phase: Direct-entry and transferred-entry participants will and self-administer intranasal esketamine (same dose) for first 4 weeks, then individualized to either once weekly or once every other week based on depressive symptoms. Maintenance Phase: All participants assigned to esketamine will self-administer intranasal esketamine once weekly or once every other week based on depressive symptoms. Placebo Optimization Phase; 166 participants: Transferred-entry participant will self-administer intranasal placebo at weekly treatment sessions for the first 4 weeks of this phase, then individualized to either once weekly or once every other week based on depressive symptoms. Maintenance Phase: Direct-entry and transferred-entry participants assigned to placebo will self-administer matching intranasal placebo once weekly or once based on depressive symptoms;Drug;D27.505.954.427.700.122
Drug: Pemetrexed;Drug: Cisplatin;Drug: Bevacizumab
Drug: Dasatinib
Drug: PAR-101/OPT-80;Drug: Vancomycin;Drug: PAR-101/OPT-80;Drug: Vancomycin;Drug: PAR-101/OPT-80;Drug: Vancomycin;Drug: PAR-101/OPT-80;Drug: Vancomycin
Drug: oseltamivir [Tamiflu]
Biological: NTHi Mcat investigational vaccine (GSK3277511A);Biological: Placebo
Drug: BAY85-3934;Drug: Placebo
Treatment as well as routine and trial specific examinations will be conducted according to the following register:<br>Baseline: study registration followed by, for imaging analysis, fluorine-18 fluordeoxyglucose positron emission tomography (18F-FDG PET-CT) scan and contrast-enhanced ultrasound<br>Day 1: treatment with cetuximab 400 mg/m^2 body surface area (bsa) will be started<br>Day 8: treatment will be continued with cetuximab 250 mg/m^2 bsa<br>Day 14 (end of treatment): imaging analysis with 18F-FDG PET-CT and a contrast-enhanced ultrasound examination<br>Day 56: evaluation of clinical response with a routine CT-scan<br><br>Between day 14 and day 56, patients will be treated according to the Folfiri-cetuximab regimen as an active and approved first-line regimen for metastatic colorectal carcinoma.
<br>Trade Name: Plavix<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Clopidogrel<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 75-<br><br>Trade Name: Locol<br>Pharmaceutical Form: Prolonged-release tablet<br>INN or Proposed INN: Fluvastatin<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 80-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>Trade Name: Zocor<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Simvastatin<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 20-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>
Drug: Amlodipine;Drug: Losartan;Drug: Atenolol
Drug: Bimekizumab;Other: Placebo
Drug: Bosutinib;Drug: imatinib
Biological: Certolizumab pegol;Biological: Placebo;Biological: Certolizumab pegol;Biological: Placebo;Biological: Certolizumab pegol;Biological: Placebo;Biological: Certolizumab pegol;Biological: Placebo
Drug: Satralizumab;Drug: Placebo;Drug: Baseline Treatment
<br>Product Code: INCB039110<br>Pharmaceutical Form: Tablet<br>Current Sponsor code: INCB039110<br>Other descriptive name: INCB039110<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Oral use<br><br>
Drug: Rimonabant (SR141716)
Drug: Eribulin mesilate;Drug: Irinotecan hydrochloride
<br>                A pre-treatment blood sample will be collected from every patient at a single time point for downstream analyses.  This sample comprises:<br>                Sample A: a whole blood EDTA sample for DNA extraction<br>                and either<br>                Sample B: a whole blood PAXgene sample for RNA extraction<br>                or<br>                Sample C: a whole blood Lithium Heparin sample for the apoptosis assay.<br><br>                Toxicity will be assessed and documented using REQUITE toxicity questionnaires based on the Common Terminology Criteria for Adverse Events (CTCAE) v4.0 and EORTC Quality of Life. At some sites additional questionnaires will also be used: Multiple Fatigue Inventory (MFI) and  the General Practice Assessment<br>                Questionnaire (GPAQ). Questionnaires will be completed at the following time points:<br>                1. Baseline assessed prior to radiotherapy (all)<br>                2. End of radiotherapy (breast and prostate); or first follow-up visit following implantation for prostate brachytherapy patients<br>                3. 3 months from start of radiotherapy (lung)<br>                4. 6 months from start of radiotherapy (lung)<br>                5. 12 months from start of radiotherapy (all)<br>                6. 24 months from start of radiotherapy (all)<br><br>                The follow-up period can be extended beyond 24 months. Further follow-up will be permissible and encouraged where possible as part of routine clinical care.<br>
Control group (Therapy A): The molar replacement by removable partial dentures, carried out using fixed crowns and bridges as anchor for removable dentures<br><br>Intervention group (Therapy B): Restorations according to the SDA concept, with only fixed restorations or no restoration at all. The maximum extension reached up to the second premolar, and no molars were replaced. All restorations were made according to a standardized procedure (SOP) given by the study protocol. <br><br>Standard gold alloys and dental ceramics were used for fixed restorations, base metal alloys for the removable denture frameworks.
Biological: Pneumococcal vaccine;Biological: Pneumococcal vaccine
Drug: Dasatinib;Drug: Imatinib;Drug: Dasatinib;Drug: Imatinib;Drug: Dasatinib;Drug: Imatinib;Drug: Dasatinib;Drug: Imatinib
Arm A: 2 x Doxorubicin, Bleomycin, Vinblastine, Dacarbazine (ABVD) and 30 Gy Involved Field Radiotherapy (IF-RT)<br>Arm B: 2 x Doxorubicin, Bleomycin, Vinblastine (ABV) and 30 Gy IF-RT<br>Arm C: 2 x Doxorubicin, Vinblastine, Dacarbazine (AVD) and 30 Gy IF-RT<br>Arm D: 2 x Doxorubicin, Vinblastine (AV) and 30 Gy IF-RT
Drug: AG-348;Drug: Placebo
Drug: Lovastatin;Drug: Lamotrigine
Drug: Olokizumab 64 mg SC q4w;Drug: Olokizumab 64 mg SC q2w;Drug: Methotrexate
Drug: Lenalidomide;Drug: Bortezomib;Drug: Dexamethasone;Drug: Isatuximab
<br>Product Name: EndoTAG-1 (lipid complexed paclitaxel)<br>Product Code: MDG 09.101<br>Pharmaceutical Form: Powder for solution for infusion<br>INN or Proposed INN: Paclitaxel <br>Current Sponsor code: MDG 09.100<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 6.40-<br><br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: Paclitaxel<br>CAS Number: 33069-62-4<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 6-<br><br>
<br>                Participants without contraindications to study medications will be randomised to receive either escitalopram or nortriptyline orally for 12 weeks. In case of non-response or adverse reaction, the treatment is terminated and, unless contraindicated, the other medication is offered for another 12 weeks. The crossover can occur at week 12 or earlier if clinically indicated with no washout period between the two treatments. Participants with a history of adverse effect, non-response or contraindication to one of the study medications are included and non-randomly allocated to the other medication. All participants will be followed up weekly for 12 weeks with an additional follow-up at week 26 from the start of the last course of medication.<br><br>                1. Escitalopram initiated at 10 mg daily and titrated to a target dose of 20 mg daily within the first two weeks if tolerated; it can be further increased to a maximum dose of 30 mg daily if clinically indicated<br>                2. Nortriptyline initiated at 50 mg daily and titrated to a target dose of 100 mg daily within the first two weeks if tolerated; further increase to a maximum dose of 200 mg daily is possible if clinically indicated<br><br>                Participants without contraindications to study medications will be randomised to receive either escitalopram or nortriptyline for 12 weeks. In case of non-response or adverse reaction, the treatment is terminated and, unless contraindicated, the other medication is offered for another 12 weeks. Participants with a history of adverse effect, non-response or contraindication to one of the study medications are included and non-randomly allocated to the other medication.<br>
Drug: Levosimendan;Drug: Placebo
Drug: TRx0237 150 mg/day;Drug: TRx0237 250 mg/day;Drug: Placebo
Drug: Fondaparinux 2.5mg or placebo;Drug: Fondaparinux 2.5mg or placebo;Drug: Fondaparinux 2.5mg or placebo;Drug: Fondaparinux 2.5mg or placebo
Drug: BMS-852927;Drug: BMS-852927;Drug: BMS-852927;Drug: Placebo
1. Lithium monotherapy<br>2. Valproate semisodium monotherapy<br>3. Lithium plus valproate semisodium combination therapy
<br>Trade Name: Lartruvo®<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: Olaratumab<br>CAS Number: 1024603-93-7<br>Other descriptive name: OLARATUMAB<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 10-<br><br>Trade Name: CARDIOXANE®<br>Product Name: Dexrazoxan<br>Pharmaceutical Form: Powder for solution for infusion<br>INN or Proposed INN: DEXRAZOXANE<br>CAS Number: 24584-09-6<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 500-<br><br>Product Name: Doxorubicinhydrochlorid <br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: DOXORUBICIN HYDROCHLORIDE<br>Other descriptive name: Doxorubicin<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 2-<br><br>
<br>                Trade Name: Temodal<br>                Product Name: Temozolomide<br>                Pharmaceutical Form: Capsule, hard<br><br>
<br>Product Name: Aclidinium Bromide<br>Product Code: LAS34273<br>Pharmaceutical Form: Inhalation powder<br>INN or Proposed INN: Aclidinium Bromide<br>CAS Number: 320345-99-1<br>Current Sponsor code: LAS34273<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 200-<br>Pharmaceutical form of the placebo: Inhalation powder<br>Route of administration of the placebo: Inhalation use<br><br>;<br>Product Name: Aclidinium Bromide<br>Product Code: LAS34273<br>Pharmaceutical Form: Inhalation powder<br>INN or Proposed INN: Aclidinium Bromide<br>CAS Number: 320345-99-1<br>Current Sponsor code: LAS34273<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 200-<br>Pharmaceutical form of the placebo: Inhalation powder<br>Route of administration of the placebo: Inhalation use<br><br>
Modification of treatment mode, frequency, drawing and analysis of blood samples
1. Targeted-volume application guided by oesophageal Doppler; only during the primary operation<br>2. Post-operative directives versus conventional volume application; only during the time the patient is in the intensive care unit (ICU)/intermediate care unit (IMCU) to finish post-operative directives (POD) 0 on the first post-operative day one at 8 am.<br><br>The follow-up will be up hospital discharge or up to the 30th post-operative day. The patient will be contacted 90 days after the operation.
Drug: AMG 386;Drug: Paclitaxel;Drug: AMG 386 Placebo;Drug: Carboplatin;Drug: AMG 386;Drug: Paclitaxel;Drug: AMG 386 Placebo;Drug: Carboplatin;Drug: AMG 386;Drug: Paclitaxel;Drug: AMG 386 Placebo;Drug: Carboplatin;Drug: AMG 386;Drug: Paclitaxel;Drug: AMG 386 Placebo;Drug: Carboplatin
<br>Product Code: K-877<br>Pharmaceutical Form: Film-coated tablet<br>CAS Number: 848259-27-8<br>Current Sponsor code: K-877<br>Other descriptive name: K-877<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 50-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>Product Code: K-877<br>Pharmaceutical Form: Film-coated tablet<br>CAS Number: 848259-27-8<br>Current Sponsor code: K-877<br>Other descriptive name: K-877<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 100-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>Product Code: K-877<br>Pharmaceutical Form: Film-coated tablet<br>CAS Number: 848259-27-8<br>Current Sponsor code: K-877<br>Other descriptive name: K-877<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 200-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>
<br>                The intervention involves elements of local consensus formation, antibiotic prescription feedback, and communication training. Training of the intervention group will be organized within small group sessions.<br><br>                Control: Care as usual<br>
Drug: Ofatumumab;Drug: Ofatumumab;Drug: Ofatumumab;Drug: Ofatumumab;Drug: Ofatumumab;Drug: Ofatumumab;Drug: Ofatumumab;Drug: Ofatumumab
<br>Product Name: ocrelizumab<br>Product Code: RO 496-4913<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: ocrelizumab<br>Current Sponsor code: RO 496-4913<br>Other descriptive name: RhuMAb 2H7<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br>Pharmaceutical form of the placebo: Concentrate for solution for infusion<br>Route of administration of the placebo: Intravenous use<br><br>
Drug: PCI-32765;Drug: PCI-32765;Drug: PCI-32765;Drug: PCI-32765
Drug: peginterferon alfa-2a [Pegasys];Drug: peginterferon alfa-2a [Pegasys];Drug: peginterferon alfa-2a [Pegasys];Drug: peginterferon alfa-2a [Pegasys]
<br>Product Name: Muxan 0,5%<br>Pharmaceutical Form: Ointment<br>INN or Proposed INN: Tosylchloramide sodium<br>CAS Number: 127-65-1<br>Other descriptive name: Chloramine-T<br>Concentration unit: % (W/W) percent weight/weight<br>Concentration number: 0,5-<br><br>Product Name: Muxan 1%<br>Pharmaceutical Form: Ointment<br>INN or Proposed INN: Tosylchloramide sodium<br>CAS Number: 127-65-1<br>Other descriptive name: Chloramine-T<br>Concentration unit: % (W/W) percent weight/weight<br>Concentration number: 1-<br><br>Product Name: Muxan 2%<br>Pharmaceutical Form: Ointment<br>INN or Proposed INN: Tosylchloramide sodium<br>CAS Number: 127-65-1<br>Other descriptive name: Chloramine-T<br>Concentration unit: % (W/W) percent weight/weight<br>Concentration number: 2-<br><br>Trade Name: Zovirax® Lippenherpescreme<br>Pharmaceutical Form: Cream<br>INN or Proposed INN: Aciclovir<br>CAS Number: 59277-89-3<br>Other descriptive name: Acycloguanosine<br>Concentration unit: % (W/W) percent weight/weight<br>Concentration number: 5-<br><br>
18 care centres in Berlin will be randomised to the intervention or control conditions:<br>1. Intervention centres:<br>1.1. 20 hours of training for nursing staff on causes, symptomatology and treatment of neuropsychiatric symptoms in dementia <br>1.2. 4 hours of training for primary care psychiatrists on causes and medical treatment of neuropsychiatric symptoms in dementia <br>1.3. 15 minute individual occupational therapy sessions twice a week<br>1.4. Provision of and training in standardized assessments of neuropsychiatric symptoms in dementia (nursing staff)<br>2. Control centres: treatment as usual<br><br>The total duration of the intervention and follow up will be 9 months
Treatment with subcutaneous injections of DiaPep277 or placebo in three different treatment groups with different schedules for a period of approximately 18-20 months. Follow up until 2 years after the first administration of study drug.<br><br>Group A: Administration of 1 mg DiaPep277 or placebo at the start of the study and 1 month, 6 months, 12 months and 18 months later. In total five administrations.<br>Group B: Administration of 1 mg DiaPep277 or placebo at the start of the study and 2 weeks, 4 weeks, 6 weeks and 8 weeks later. Further administrations in intervals of approximately 3 months. In total 10 administrations.<br>Group C: Administration of 0.2 mg DiaPep277 or placebo at the start of the study and 2 weeks, 4 weeks, 6 weeks and 8 weeks later. This course is repeated 6 months, 12 months and 18 months after the first administration. In total 20 administrations.
Drug: CS-1008;Drug: Placebo;Drug: Paclitaxel;Drug: Carboplatin
<br>Trade Name: Katadolon 100mg, Hartkapsel<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: FLUPIRTINE MALEATE<br>CAS Number: 75507-68-5<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br>Pharmaceutical form of the placebo: Capsule, hard<br>Route of administration of the placebo: Oral use<br><br>
NULL
Drug: Ibrutinib;Drug: Gemcitabine;Drug: Nab-paclitaxel
Drug: Ramucirumab;Drug: Merestinib;Drug: Cisplatin;Drug: Gemcitabine;Drug: Placebo Oral;Drug: Placebo IV
Subjects will receive 4 cycles of Abraxane (Investigational Product) (125mg/m2) intravenously over 30 min given week 1, 2 and 3 followed by 1 week rest or the comparator. This will be followed by 4 cycles of anthracycline-containing chemotherapy (AC/EC or FEC - based on clinician decision). AC Doxorubicin 60mg/m2, Cyclophosphamide 600mg/m2 intravenously over 30 min given once every 3 weeks;  EC Epirubicin 90mg/m2, Cyclophosphamide 600mg/m2 intravenously over 30 min given once every 3 weeks; FEC Fluorouracil 600mg/m2 Epirubicin 90mg/m2 Cyclophosphamide 600mg/m2 intravenously over 30 min given once every 3 weeks
Intervention1: Necitumumab IMC-11F8 (16mg/ml), intravenous infusion:: Patients will receive IMC-11F8 (2 x 800 mg per three week cycle) until there is documentation of Progression of Disease, unacceptable toxicity, or withdrawal of consent, or until other withdrawal criteria are met.<br>Intervention2: Pemetrexed (500mg):: intravenous infusion 500mg/m&sup2; per cycle for 6 three-week cycles<br><br><br>Intervention3: Cisplatin ((0.5mg/ml):: intravenous infusion  75 mg/m&sup2; per cycle for 6 three-week cycles<br><br><br>Control Intervention1: Nil: Nil<br>
Drug: Enfuvirtide
1. Intervention group:<br>Pro-Symbioflor® (verum): Bacterial lysate manufactured from 1,5 ? 4,5 x 10E+07 Enterococcus faecalis (DSM 16440) and 1,5 ? 4,5 x 10E+07 Escherichia coli (DSM 17252). 3x5 drops per day for 2 weeks then increased to 3x10 drops per day between 2 and 7 months of age.<br>2. Control group:<br>Pro-Symbioflor® (placebo): Culture medium without bacteria. 3x5 drops daily, for 2 weeks  increased to 3x10 drops daily between 2 and 7 months of age. <br><br>The total duration of follow up will be 3 years.
Drug: Lapatinib;Drug: Pemetrexed;Drug: Lapatinib;Drug: Pemetrexed;Drug: Lapatinib;Drug: Pemetrexed;Drug: Lapatinib;Drug: Pemetrexed
Drug: Lenabasum 5 mg;Drug: Lenabasum 20 mg;Other: Placebo oral capsule
<br>Trade Name: Afinitor 2,5mg<br>Product Name: everolimus<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: everolimus<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 2,5-<br><br>Trade Name: dexamethasone<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: Dexamethasone<br><br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: Cytarabine<br><br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: Cisplatin<br><br>Trade Name: Afinitor 5,0mg<br>Product Name: everolimus<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: Everolimus<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 5-<br><br>
<br>Product Name: Gentamicin 0.1%_Betamethasone 0.05% Ointment<br>Pharmaceutical Form: Ointment<br>CAS Number: 5593-20-4<br>Other descriptive name: BETAMETHASONE DIPROPIONATE<br>Concentration unit: % (W/W) percent weight/weight<br>Concentration type: equal<br>Concentration number: 0.05-<br>INN or Proposed INN: GENTAMICIN SULFATE<br>CAS Number: 1405-41-0<br>Concentration unit: % (W/W) percent weight/weight<br>Concentration type: equal<br>Concentration number: 0.1-<br>Pharmaceutical form of the placebo: Ointment<br>Route of administration of the placebo: Cutaneous use<br><br>Trade Name: Diprogenta Ointment<br>Product Name: Diprogenta Ointment<br>Pharmaceutical Form: Ointment<br>CAS Number: 5593-20-4<br>Other descriptive name: BETAMETHASONE DIPROPIONATE<br>Concentration unit: mg/g milligram(s)/gram<br>Concentration type: equal<br>Concentration number: 0.64-<br>INN or Proposed INN: GENTAMICIN SULFATE<br>CAS Number: 1405-41-0<br>Concentration unit: mg/g milligram(s)/gram<br>Concentration type: equal<br>Concentration number: 1.67-<br><br>
Drug: Epratuzumab;Drug: Epratuzumab;Drug: Placebo
Drug: milnacipran;Drug: Placebo
<br>Trade Name: Sebivo<br>Product Name: Sebivo<br>Pharmaceutical Form: Tablet<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Oral use<br><br>
Drug: BIBF 1120;Drug: BIBF 1120;Drug: BIBF 1120;Drug: BIBF 1120
Patients affected by different forms of CDT will be included in the study. All patients will undergo CPET as well as stress echocardiography to detect secondary PH. Based on general disease characteristics and CPET results a diagnostic value will be assessed to provide a prospective measure for the early detection of PH in CDT. Second, it will attempted to assess a severity classification based on CPET and stress echocardiography.